Zepbound: Eli Lilly new weight-loss drug 20% cheaper than Wegovy
- “Miracle Weight-Loss Drug” Sweeps Across America
- The United States Avian Influenza Outbreak Worse Than Expected?
- Global First: Bovine Avian Influenza Transmission to Humans Detected
- Potassium-Enriched Salt Substitutes: Reducing Blood Pressure Risk?
- Tritium Detection in Fukushima’s Seawater: Below Safety Standards
- What Reason Let AstraZeneca Withdraws COVID Vaccine From The Market?
Zepbound: Eli Lilly new weight-loss drug 20% cheaper than Wegovy
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Zepbound: Eli Lilly new weight-loss drug 20% cheaper than Wegovy
“Zepbound,” Eli Lilly’s new weight-loss drug, is officially on the market in the United States, offering a 20% cost advantage over Wegovy.
On Dec 05, pharmaceutical giant Eli Lilly announced the availability of its weight-loss drug, Zepbound, in U.S. pharmacies for adults struggling with severe obesity.
In the midst of ongoing shortages of weight-loss medications, Zepbound provides an alternative for consumers.
In the stock market, Eli Lilly’s shares saw a slight increase of 0.15%, while Novo Nordisk fell by 1.5%.
Eli Lilly stated that patients with a prescription from their doctors can now access Zepbound, which has been added to the preferred drug lists of Express Scripts and Cigna this month. The company also plans to invest in expanding production to meet the growing demand for innovative medications, making Zepbound accessible to millions of Americans.
Zepbound marks Eli Lilly’s first drug specifically targeting obesity, and it is expected that the weight-loss drug market will reach approximately $100 billion by the end of this decade. Zepbound has already been included in the national preferred drug list by at least one major health insurance company.
According to the company, Zepbound is suitable for adults with obesity and those who are overweight, as well as individuals requiring weight loss and maintenance due to health issues such as weight-related hypertension, type 2 diabetes, and cardiovascular diseases.
The primary component of Zepbound is Tirzepatide, which mimics hormones, stimulates insulin release, increases satiety, and reduces appetite. It targets two hormone receptors, GIP and GLP-1, while Novo Nordisk’s semaglutide only targets GLP-1.
Since 2022, Eli Lilly’s Tirzepatide has been marketed as Mounjaro for treating type 2 diabetes and has become a popular off-label weight-loss drug, leading to periodic shortages in supply.
Rhonda Pacheco, Vice President of Diabetes and Obesity at Eli Lilly, stated in a release, “We must collaborate with employers, governments, and healthcare industry partners to eliminate barriers and make Zepbound accessible to those in need.”
Eli Lilly plans to launch six doses of Zepbound in the U.S., ranging from 2.5mg to 15mg, with a price tag of $1,059.87 per month. In comparison, Novo Nordisk’s popular weight-loss drug Wegovy is priced at $1,349 per month.
By participating in Eli Lilly’s ongoing commercial savings card program, individuals can obtain Zepbound at a lower cost. Under this plan, those with commercial insurance covering Zepbound are eligible to pay a minimum fee of $25 for a one- or three-month prescription. Individuals with commercial insurance but not covering Zepbound may pay as low as $550 for a one-month Zepbound prescription, approximately 50% lower than the regular price.
Bloomberg Intelligence analyst Michael Shah believes that the combination of a lower price and improved weight-loss efficacy could lead to wider adoption of Zepbound over Wegovy. He adds that by 2030, Zepbound’s sales could surpass $26 billion.
Prior to the launch of Zepbound, Eli Lilly’s stock price had surged by 60% this year, making the pharmaceutical company the most valuable healthcare company globally.
Zepbound: Eli Lilly new weight-loss drug 20% cheaper than Wegovy
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.